BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 19, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2000

View Archived Issues

Sepracor completes large-scale U.S. efficacy study of (S)-zopiclone

Read More

Orally active ester prodrug of alphavbeta3 antagonist effective in rat model of osteoporosis

Read More

SmithKline Beecham to divest Kytril, Famvir and Vectavir/Denavir

Read More

Taxotere combination therapy approved in E.U. for treatment of advanced breast cancer

Read More

Novel treatment for asthma --an IL-4/IL-13 receptor antagonist-- characterized at ERS meeting

Read More

Ebselen as a new therapeutic agent for asthma

Read More

One-year treatment with UT-15 improves hemodynamics, exercise tolerance in PPH

Read More

ACS news: selective inhibitors of ICAM-1/E-selectin expression exerting antiinflammatory activity

Read More

XTL Biopharmaceuticals and Hybrigenics to codevelop novel HCV therapeutics

Read More

R&D at Pharmacia in the area of CETP inhibitors discussed at ACS meeting

Read More

Serono acquires exclusive rights to Cetrotide; U.S. launch planned

Read More

Noncompetitive dihydrophthalazine AMPA receptor antagonists synthesized at Annovis

Read More

Actelion continues development of tezosentan and bosentan as planned

Read More

ZD-6021: a potent, orally active tachykinin receptor antagonist

Read More

Phylos achieves key milestones in Amgen drug discovery collaboration

Read More

Supratek's SP-1017 shown to significantly increase gene expression

Read More

Aventis characterizes potential novel antiasthmatic agent

Read More

Sequenom and PHRI to develop high-speed diagnostic tests for MDR tuberculosis

Read More

Ortec's treatment for venous ulcers continues to demonstrate superiority

Read More

PARP inhibitors reportedly useful in combination with cytotoxic agents

Read More

Ranbaxy's new cell adhesion inhibitors with antiinflammatory activity

Read More

Amides with cholinergic activity and their use disclosed by Fujisawa

Read More

Endothelin receptor antagonists designed by Roche

Read More

MEK inhibitors and their use described in recent patents

Read More

DuPont patent describes new HIV protease inhibitors

Read More

New antitumor compound from Banyu produced by microorganism

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Rare disease illustration

    Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

    BioWorld
    Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing